These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 30655980

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis.
    Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M.
    Cancer; 2001 Oct 25; 93(5):344-50. PubMed ID: 11668470
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
    Jeong ISD, Moyers J, Thung I, Thinn MM.
    Am J Case Rep; 2020 Jun 30; 21():e925181. PubMed ID: 32601266
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature.
    You Y, Wang P, Wan X, Xu L, Gong Y, Zhang W.
    Onco Targets Ther; 2021 Jun 30; 14():3481-3486. PubMed ID: 34093024
    [Abstract] [Full Text] [Related]

  • 15. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
    Boon E, Bel M, van Boxtel W, van der Graaf WTA, van Es RJJ, Eerenstein SEJ, Baatenburg de Jong RJ, van den Brekel MWM, van der Velden LA, Witjes MJH, Hoeben A, Willems SM, Bloemena E, Smit LA, Oosting SF, PALGA Group, Jonker MA, Flucke UE, van Herpen CML.
    Int J Cancer; 2018 Aug 15; 143(4):758-766. PubMed ID: 29492965
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.
    Saigusa N, Hirai H, Tada Y, Kawakita D, Nakaguro M, Tsukahara K, Kano S, Ozawa H, Kondo T, Okami K, Togashi T, Sato Y, Urano M, Kajiwara M, Shimura T, Fushimi C, Shimizu A, Okamoto I, Okada T, Suzuki T, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Takahashi H, Ando M, Kohsaka S, Matsuki T, Nagao T.
    Front Oncol; 2021 Aug 15; 11():779882. PubMed ID: 35186711
    [Abstract] [Full Text] [Related]

  • 18. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
    Yang RK, Zhao P, Lu C, Luo J, Hu R.
    Hum Pathol; 2019 Feb 15; 84():173-182. PubMed ID: 30267779
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
    van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E, Cavalieri S, Tooten S, Bos E, Quattrone P, Verhaegh GW, Schalken JA, Licitra L, van Herpen CML, PALGA Group.
    Eur J Cancer; 2019 Mar 15; 110():62-70. PubMed ID: 30771738
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.